Point Biopharma
Indianapolis
About Point Biopharma
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $310.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2022)
- Ticker: nasdaq:PNT
- Website: pointbiopharma.com
- Phone: (317) 543-9957
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/point-biopharma-4667 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.